Abstract
Bladder lesion commonly occurs in patients with benign prostatic hyperplasia (BPH), and routine screening is vital for timely detection. Current clinical methods like cystoscopy are invasive and inconvenient for routine use. This study proposes a non-invasive screening method using machine learning to diagnose bladder lesions based on routine clinical risk factors. Using a cohort of 253 BPH patients, the model identified bladder compliance, maximum flow rate (Qmax), prostate-specific antigen (PSA), and postvoid residual (PVR) as the primary predictors. The Support Vector Machine (SVM) model achieved high precision (86.83%) and interpretability via SHAP analysis, offering a potential routine screening tool.
Introduction
Bladder lesions, including diverticula and trabeculation, are frequent complications of Benign Prostatic Hyperplasia (BPH). If undetected, these can progress to severe conditions like acute renal failure or bladder cancer. The current diagnostic "gold standard," cystoscopy, is invasive and uncomfortable, making it unsuitable for frequent screening. While imaging like MRI or CT exists, costs and technical requirements limit their routine application. This research addresses the need for a low-cost, non-invasive "white-box" screening tool using standard clinical metrics.
Methods
The study utilized a retrospective cohort of 253 male BPH patients (172 with lesions, 81 controls). Six routine clinical factors were analyzed: bladder compliance, Qmax, PSA, PVR, detrusor contractility, and IPSS/QoL scores.
The researchers compared six machine learning architectures, including Support Vector Machines (SVM), Random Forest, and Multi-Layer Perceptron. To address class imbalance, the Synthetic Minority Over-sampling Technique (SMOTE) was applied. Crucially, the team integrated SHAP (Shapley Additive Explanations) to provide interpretability, allowing clinicians to understand the specific factors driving each diagnostic prediction.
Results
The SVM model emerged as the top performer, balancing high accuracy with clinical reliability. It achieved a precision of 86.83% and an Area Under the Curve (AUC-ROC) of 0.8055.
Beyond raw performance, the study identified the "Big Four" predictors: bladder compliance, Qmax, PSA, and PVR. Threshold analysis pinpointed specific clinical "tipping points" for increased risk, such as a PVR greater than 172.49 cc or a Qmax below 8.13 ml/s. Subjective symptom scores (IPSS) were found to be the least reliable predictors.
Discussion and Future Work
While promising, the study's single-center nature and relatively small sample size necessitate further validation in multi-center trials. Future work aims to incorporate urinary biomarkers to enhance accuracy and explore deep learning models to capture more complex clinical relationships. This interpretable framework represents a significant step toward non-invasive, routine screening for bladder lesions in BPH patients.
Summary updated